Biodistribution of covalent antithrombin-heparin complexes

Summary

We have developed a covalent antithrombin-heparin (ATH) complex with advantages compared to non-covalent antithrombin: heparin (AT:H) mixtures. In addition to increased activity, ATH has a longer intravenous half-life that is partly due to reduced plasma protein binding. Given ATH’s altered clearance, we investigated biodistribution of ATH in vivo. ATH made from either human plasma-derived AT (pATH) or recombinant human (produced in goats) AT (rhATH) was studied. ¹²⁵I-ATH + unlabeled carrier was injected into rabbits at different doses. ¹³¹Ilabeled albumin was administered just before sacrifice as a marker for trapped blood in tissues. Immediately after sacrifice, animal components were removed, weighed, and subsamples were counted for gamma-radioactivity. Percent recoveries of ATH in various organs/compartments at different time points were calculated, and kinetic distribution plots generated. At saturating doses, early disappearance of rhATH from the circulation was much faster than pATH. Co-incident with clearance, 26 ± 3 % of dose for rhATH was liver-associated compared to only 3.7 ± 0.5 % for pATH by 20 min. Also, at early time periods, > 60% of all extravascular ATH was liver-associated. Analysis of the vena cava and aorta suggested that vessel wall binding might also account for initial plasma loss of rhATH. By 24 h, most of pATH and rhATH were present as urinary degradation products (51 ±3 % and 63 ±8 %, respectively). In summary, systemic elimination of ATH is greatly influenced by the form of AT in the complex, with liver uptake and degradation playing a major role.

Keywords

Antithrombin - heparin - pharmacodynamics

Footnote: Anthony Chan is a career investigator of the Heart and Stroke Foundation of Canada.

• References

• 1 Paredes N, Wang A, Berry LR. et al. Mechanisms responsible for catalysis of the inhibition of factor Xa or thrombin by antithrombin using a covalent antithrombin-heparin complex. J Biol Chem 2003; 278: 23398-409.
• 2 Becker DL, Fredenburgh JC, Stafford AR. et al. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. J Biol Chem 1999; 274: 6226-33.
• 3 Chan AK, Berry L, O’Brodovich H. et al. Covalent antithrombin-heparin complexes with high anticoagulant activity: Intravenous, subcutaneous and intratracheal administration. J Biol Chem 1997; 272: 22111-7.
• 4 Berry L, Stafford A, Fredenburgh J. et al. Investigation of the anticoagulant mechanisms of a covalent antithrombin-heparin complex. J Biol Chem 1998; 273: 34730-6.
• 5 Berry L, Andrew M, Chan AKC. Antithrombin-heparin complexes. In: Polymeric Biomaterials. Part II: Medical and pharmaceutical applications of polymers. Dumitriu S. 2nd ed. New York: Marcel Dekker Inc; 2002: 669-702.
• 6 Chan AK, Berry L, Mitchell L. et al. Effect of a novel covalent antithrombin-heparin complex on thrombin generation on fetal distal lung epithelium. Am J Physiol 1998; 274: L914-21.
• 7 Berry LR, Andrew M, Chan AKC. Effect of covalent serpin-heparinoid complexes on plasma thrombin generation on fetal distal lung epithelium. Am J Resp Cell Mol Biol 2003; 28: 150-8.
• 8 Berry LR, Becker DL, Chan AK. Inhibition of fibrin-bound thrombin bya covalent antithrombin-heparin complex. J Biochem (Tokyo) 2002; 132: 167-76.
• 9 Chan AKC, Rak J, Berry LR. et al. Antithrombinheparin covalent complex: a possible alternative to heparin for arterial thrombosis prevention. Circulation 2002; 106: 261-5.
• 10 Chan AK, Berry L, Klement P. et al. A novel antithrombin-heparin covalent complex: antithrombotic and bleeding studies in rabbits. Blood Coagul Fibrinolysis 1998; 09: 587-95.
• 11 Chan AKC, Paredes N, Thong B. et al. Binding of heparin to plasma proteins and endothelial surfaces is inhibited by covalent linkage to antithrombin. Thromb Haemost 2004; 91: 1009-18.
• 12 Lane DA, Pijler G, Flynn AM. Neutralization of heparin related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem 1986; 261: 3980-6.
• 13 Manson L, Weitz JI, Podor TJ. et al. The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance. J Lab Clin Med 1997; 130: 649-55.
• 14 Tsuchida S, Engelberts D, Roth M. et al. Continuous postive airway pressure causes lung injury in a model of sepsis. Am J Physiol Lung Cell Mol Physiol 2005; 289: L554-64.
• 15 Schmidt B, Gillie P, Mitchell L. et al. A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. Am J Respir Crit Care Med 1998; 158: 470-6.
• 16 Chan AK, Baranowski B, Berry L. et al. Influence of mechanical stretch on thrombin regulation by mixed fetal lung epithelial cells. Am J Resp Cell Mol Biol 1998; 19: 419-25.
• 17 Chan AKC, Tressel P, Weitz J. et al. Novel antithrombotic drug reduces arterial doppler high intensity transient signals during and after hypothermic cardiopulmonary bypass in pigs. Circulation 2003; 108: 433.
• 18 GTC Biotherapeutics. Recombinant human antithrombin III: rhATIII. Drugs R D 2004; 05: 110-2.
• 19 Hatton MW, Berry LR, Regoeczi E. Inhibition of thrombin by antithrombin III in the presence of certain glycosaminoglycans found in the mammalian aorta. Thromb Res 1978; 13: 655-70.
• 20 Lightfoot EN. Transport Phenomena and Living Systems. Biomedical aspects of momentum and mass transport. Toronto: John Wiley and Sons; 1974
• 21 Pries AR, Secomb TW, Gaehtgens P. The endothelial surface layer. Pflugers Arch 2000; 440: 653-66.
• 22 Hirsh J, van Aken WG, Gallus AS. et al. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976; 53: 691-5.
• 23 Hirsh J, Warkentin TE, Raschke R. et al. Heparin and low molecular weight heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114: 489S-510S.
• 24 Weitz JI, Hudoba M, Massel D. et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III independent inhibitors. J Clin Invest 1990; 86: 385-91.
• 25 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619-23.
• 26 Bendayan P, Boccalon H, Dupouy D. et al. Dermatan sulphate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. Thromb Haemostas 1994; 71: 576-84.
• 27 Chan AKC, Berry L, Klement P. et al. A novel antithrombin-heparin covalent complex: Antithrombotic and bleeding studies in rabbits. Blood Coagul Fibrinolysis 1998; 09: 587-95.
• 28 Schwartz AL. Receptor cell biology: receptor-mediated endocytosis. Pediatr Res 1995; 38: 835-43.
• 29 Fadin M, Boldrin M, Gavasso S. et al. Levels of anti-thrombin III activity in the plasma of cynomolgus monkeys after administration of recombinant human anti-thrombin III. J Thromb Haemost 2003; 01: P1011.
• 30 Levy JH, Despotis GL, Olson P. et al. Transgenically produced recombinant human ATIII enhances the antithrombotic effects of heparin in patients undergoing cardiac surgery. Blood 1997; 90: 1318a.
• 31 Regoeczi E. Distribution of antithrombin III in rabbits: role of host and protein. Am J Physiol 1987; 252: R457-61.
• 32 Sie P, Lansen J, Lacheretz F. et al. Comparative turn-over of heparin cofactor II and antithrombin III in baboons. Influence of heparin and pentosan polysulfate administration. Thromb Haemost 1986; 56: 302-7.
• 33 Knot EAR, de Jong E, ten Cate JW. et al. Antithrombin III: biodistribution in healthy volunteers. Thromb Haemostas 1987; 58: 1008-11.
• 34 Manson HE, Austin RC, Fernandez-Rachubinski F. et al. The molecular pathology of inherited human antithrombin III deficiency. Transfus Med Rev 1989; 03: 264-81.
• 35 Carlson TH, Kolman MR, Piepkorn M. Activation of antithrombin III isoforms by heparan sulphate glycosaminoglycans and other sulphated polysaccharides. Blood Coagul Fibrinolysis 1995; 06: 474-80.
• 36 Witmer MR, Hatton MW. Antithrombin III-beta associates more readily than antithrombin III-alpha with uninjured and de-endothelialized aortic wall in vitro and in vivo . Arterioscler Thromb 1991; 11: 530-9.
• 37 Edmunds T, Van Patten SM, Pollock J. et al. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood 1998; 91: 4561-71.
• 38 Zhou Q, Kyazike J, Echelard Y. et al. Effect of genetic background on glycosylation heterogeneity in human antithrombin produced in the mammary gland of transgenic goats. J Biotechnol 2005; 117: 57-72.
• 39 Pizzo SV. Serpin receptor 1: a hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes. Am J Med 1989; 87: 10S-4S.
• 40 Carlson TH, Simon TL, Atencio AC. In vivo behaviour of human radioiodinated antithrombin III: distribution among three physiologic pools. Blood 1985; 66: 13-9.
• 41 Mushunje A, Evans G, Brennan SO. et al. Latent antithrombin and its detection, formation and turnover in the circulation. J Thromb Haemost 2004; 02: 2170-7.
• 42 Camani C, Kruithof EK. Clearance receptors for tissue-type plasminogen activator. Int J Hematol 1994; 60: 97-109.
• 43 Rijken DC, Otter M, Kuiper J. et al. Receptor-mediated endocytosis of tissue-type plasminogen activator (t-PA) by liver cells cells. Thromb Res 1990; 10: 63-71.
• 44 Ezekowitz RA, Stahl PD. The structure and function of vertebrate mannose lectin-like proteins. J Cell Sci 1988; 09: 121-33.
• 45 Justus AC, Roussev R, Norcross JL, Faulk WP. Antithrombin binding by human umbilical vein endothelial cells: effects of exogenous heparin. Thromb Res 1995; 79: 175-86.
• 46 Linehan SA. The mannose receptor is expressed by subsets of APC in non-lymphoid organs. BMC Immunol 2005; 06: 4.
• 47 Higuchi Y, Nishikawa M, Kawakami S. et al. Uptake characteristics of mannosylated and fucosylated bovine serum albumin in primary cultured rat sinusoidal endothelial cells and Kupffer cells. Int J Pharm 2004; 287: 147-54.
• 48 Archer SL. Diversity of phenotype and function of vascular smooth muscle cells. J Lab Clin Med 1996; 127: 524-9.
• 49 Sheikh H, Yarwood H, Ashworth A. et al. Endo180, an endocytic recycling glycoprotein related to the macrophage mannose receptor is expressed on fibroblasts, endothelial cells and macrophages and functions as a lectin receptor. J Cell Sci 2000; 113: 1021-32.
• 50 Groger M, Holnthoner W, Maurer D. et al. Dermal microvascular endothelial cells express the 180-kDa macrophage mannose receptor in situ and in vitro . J Immunol 2000; 165: 5428-34.
• 51 Takahashi K, Donovan MJ, Rogers RA. et al. Distribution of murine mannose receptor expression from early embryogenesis through to adulthood. Cell Tissue Res 1998; 292: 311-23.
• 52 Absher E, Labarrere CA, Carter C. et al. The endothelial heparan sulfate-antithrombin III natural anticoagulant pathway in normal and transplanted human kidneys. Transplantation 1992; 53: 828-34.
• 53 Mertens G, Cassiman JJ, Van Den Berghe H. et al. Cell surface heparan sulfate proteoglycans from human vascular endothelial cells. Core protein characterization and antithrombin III binding properties. J Biol Chem 1992; 267: 20435-43.
• 54 Mammen EF. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 1998; 24: 19-25.
• 55 Sanchez J, Olsson P. On the control of the plasma contact activation system on human endothelium: comparisons with heparin surface. Thromb Res 1999; 93: 27-34.
• 56 Bensley BA. Practical Anatomy of the Rabbit: An Elementary Laboratory Textbook in Mammalian Anatomy. Toronto: University of Toronto; 1948
• 57 Brown BP, Heistad DD. Capacitance of the rabbit portal vein and inferior vena cava. J Physiol 1986; 381: 417-25.
• 58 Orlandi A, Mauriello A, Marino B. et al. Age-related modifications of aorta and coronaries in the rabbit: a morphological and morphometrical assessment. Arch Gerontol Geriatr 1993; 17: 37-53.
• 59 Klement P, Du YJ, Berry L. et al. Blood-compatible biomaterials by surface coating with a novel antithrombin-heparin covalent complex. Biomaterials 2002; 23: 527-35.